
MK-0354
CAS No. 851776-28-8
MK-0354( MK0354 )
Catalog No. M16190 CAS No. 851776-28-8
MK-0354 is a potent, selective niacin receptor GPR109A partial agonist with EC50 of 1.65 and 1.08 uM for hGPR109A and mGPR109A in the whole cell cAMP assays.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
50MG | 776 | Get Quote |
![]() ![]() |
100MG | Get Quote | Get Quote |
![]() ![]() |
200MG | Get Quote | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameMK-0354
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK-0354 is a potent, selective niacin receptor GPR109A partial agonist with EC50 of 1.65 and 1.08 uM for hGPR109A and mGPR109A in the whole cell cAMP assays.
-
DescriptionMK-0354 is a potent, selective niacin receptor GPR109A partial agonist with EC50 of 1.65 and 1.08 uM for hGPR109A and mGPR109A in the whole cell cAMP assays; shows no interaction with any other target in a panel of over 120 other proteins; MK-0354 is a competitive inhibitor of 3H-nicotinic acid binding to hGPR109a with Ki of 505 nM, fully inhibits isoproterenol stimulated lipolysis in human adipocytes with IC50 of 3.1 uM, also is a competitive antagonist of nicotinic acid-induced MAPK signaling in cells overexpressing either mGPR109a or hGPR109a; possesses plasma FFA lowering effects in mice comparable to those of nicotinic acid, does not induce vasodilation.Atherosclerosis Phase 2 Discontinued.
-
In Vitro——
-
In Vivo——
-
SynonymsMK0354
-
PathwayGPCR/G Protein
-
TargetGPR119
-
RecptorGPR119
-
Research AreaCardiovascular Disease
-
IndicationAtherosclerosis
Chemical Information
-
CAS Number851776-28-8
-
Formula Weight176.1786
-
Molecular FormulaC7H8N6
-
Purity>98% (HPLC)
-
SolubilityDMSO: ≥ 36 mg/mL
-
SMILESC12=C(CCC2)C(C3=NN=NN3)=NN1
-
Chemical NameCyclopentapyrazole, 1,4,5,6-tetrahydro-3-(2H-tetrazol-5-yl)-
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Semple G, et al. J Med Chem. 2008 Aug 28;51(16):5101-8.
2. Lai E, et al. J Clin Lipidol. 2008 Oct;2(5):375-83.
3. Walters RW, et al. J Clin Invest. 2009 May;119(5):1312-21.
4. Gaidarov I, et al. Cell Signal. 2013 Oct;25(10):2003-16.
molnova catalog



related products
-
GSK1292263
GSK1292263 is a novel potent, selective GPR119 agonist, elevates circulating glucose-dependent insulinotropic peptide.
-
Firuglipel
Firuglipel (DS-8500, DS8500a) is a novel potent, selective, orally available GPR119 agonist with EC50 of 51.5 nM in human GPR119-expressing CHO-K1 cells.
-
MK-0354
MK-0354 is a potent, selective niacin receptor GPR109A partial agonist with EC50 of 1.65 and 1.08 uM for hGPR109A and mGPR109A in the whole cell cAMP assays.